UNIVERSITY OF ILLINOIS
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1859-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.illinois.edu
Clinical Trials
474
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (430 trials with phase data)• Click on a phase to view related trials
Oral Health Intervention for Caregivers of Children Presenting for Dental Surgery
- Conditions
- Early Childhood Caries
- First Posted Date
- 2025-10-24
- Last Posted Date
- 2025-10-24
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 420
- Registration Number
- NCT07220850
- Locations
- 🇺🇸
College of Dentistry (MC 621), Chicago, Illinois, United States
CKD Awareness, Referrals, Education, and Support Intervention for Early-Stage CKD
- Conditions
- Chronic Kidney DiseaseDiabetes
- First Posted Date
- 2025-10-07
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT07210710
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
- Conditions
- AlbuminuriaSickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
- Interventions
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 20
- Registration Number
- NCT07175051
- Locations
- 🇺🇸
University of Illinois Chicago, Sickle Cell Center, Chicago, Illinois, United States
A Community Engagement Approach to Improving Communication With Black Men About Oral and Pharyngeal Cancers
- Conditions
- Oral Cancers
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT07172776
Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
- Conditions
- Intracerebral HemorrhageICH - Intracerebral Hemorrhage
- Interventions
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 240
- Registration Number
- NCT07162363
- Locations
- 🇺🇸
University of Illinois Hospital & Health Sciences System (UI Health), Chicago, Illinois, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 95
- Next
News
Hydrogel-Based mRNA Cancer Vaccine Platform Shows Promise for Enhanced Immune Response
Researchers at the University of Illinois have developed a macroporous hydrogel-based mRNA cancer vaccine platform that actively recruits dendritic cells to improve vaccine efficiency.
FDA Grants First-Ever Waiver of Clinical Efficacy Studies for Monoclonal Antibody Biosimilars
Professor Sarfaraz K. Niazi has secured the first-ever FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars, fundamentally redefining biological drug development and approval processes.
Breakthrough in Platelet Engineering Opens New Avenues for Targeted Drug Delivery
University of Illinois researchers have successfully applied metabolic glycan labeling to platelets for the first time, overcoming the challenge of engineering these nucleus-free cell fragments.